Emily Estrada

Results from a phase 2 study demonstrated that autologous NK cell consolidation following chemoradiotherapy significantly improved survival in patients with limited-stage small cell lung cancer.

Results from a phase 2 study demonstrate that ivonescimab plus liposomal irinotecan shows encouraging efficacy and safety in pretreated patients with small cell lung cancer.

Results from the phase 3 PETALs trial demonstrated that adding pegylated interferon alfa-2a to nilotinib improved early deep molecular response in newly diagnosed patients with chronic phase chronic myeloid leukemia.

Results from the HERIZON-GEA-01 trial demonstrated that zanidatamab plus chemotherapy with or without tislelizumab significantly improved outcomes in patients with HER2-positive advanced gastroesophageal adenocarcinoma.

Total marrow and lymphoid irradiation combined with high-dose etoposide and cyclophosphamide was feasible and associated with encouraging outcomes in patients with relapsed or refractory acute leukemia undergoing alloHCT, as demonstrated by...

Results from the phase 1a RevSTAR-123 study demonstrated that an investigational switchable allogeneic CD123-directed CAR T-cell therapy showed encouraging clinical activity in heavily pretreated relapsed or refractory acute myeloid leukemia.

Results from the phase 3 HOVON156/AMLSG28-18/PASHA trial demonstrated that gilteritinib did not significantly improve overall survival compared with midostaurin when combined with intensive chemotherapy in patients with newly diagnosed...

Results from an ongoing phase 1 trial demonstrated that LB2501 shows encouraging activity and promising safety in patients with relapsed or refractory non-Hodgkin lymphomas.

Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.

Results from a phase 3 trial demonstrated that post-transplant cyclophosphamide did not achieve noninferiority to anti–T-lymphocyte globulin for overall survival following unrelated donor alloHCT in patients with high-risk myeloid...